Table 1. Patient characteristics.
| Category | Number of patients | Number of recurrent patients |
|---|---|---|
| Total | 115 | 58 |
| Age, median (range, years) | 68.0 (27–88) | |
| Months of follow-up, median (range) | 26.0 (3–120) | |
| Gender (%): | ||
| Male | 92 (80.0) | 47 |
| Female | 23 (20.0) | 11 |
| Smoking (%): | ||
| Yes | 30 (26.1) | 12 |
| No | 17 (14.8) | 12 |
| Unknown | 68 (59.1) | 34 |
| pT stage (%): | ||
| pTa | 70 (60.9) | 38 |
| pT1 | 39 (33.9) | 20 |
| pTis | 6 (5.2) | 0 |
| Pathological WHO grade (%): | ||
| low grade | 78 (67.8) | 44 |
| high grade | 37 (32.1) | 14 |
| Risk stratification (%): | ||
| low-risk | 32 (27.8) | 17 |
| intermediate-risk | 45 (39.1) | 27 |
| high-risk | 38 (33.0) | 14 |
| Adjuvant intravesical treatment (%): | ||
| None | 60 (52.2) | 37 |
| THP | 32 (27.8) | 17 |
| BCG | 23 (20.0) | 4 |
| Percentage of Foxp3+ T cell (%): | ||
| < 17.1 | 58 (50.4) | 24 |
| ≥ 17.1 | 57 (49.6) | 34 |